|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Downregulation IGF2R may promote tumor growth by activating AKT signaling pathway.
|
31847523 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study demonstrates the feasibility of targeting IGF2R on OS in PDX and spontaneous canine tumors and sets the stage for further development of RIT of OS using comparative oncology.
|
31391495 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA expression levels of IGF2R were measured in primary human HCC and corresponding non‑neoplastic tumor‑surrounding tissue (TST) by reverse transcription‑polymerase chain reaction (RT‑PCR) (n=92).
|
30720132 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Regarding its antagonistic activity as an IGF1R signal, IGF2R is currently considered a tumor suppressor gene, whereas its significance as an M6P receptor is still unclear.
|
31748500 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of MDR-mediated proteins, including P-glycoprotein (P-gp), multidrug resistance-associated protein (MPR1) and lung resistance protein 1 (LPR1), was detected in tumor tissue of A549/DDP xenograft mice.
|
29541206 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
M6P/IGF2R is a multifunctional receptor involved in protein sorting, internalization, and degradation, being considered a tumor suppressor.
|
29318541 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The low IGF2R expression was significantly associated with the smoking status, higher tumor stage, and poorer differentiation status of these patients.
|
25402559 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An individual with high IGF-II expression levels has a high risk of developing cancer, but IGF2R is often considered to be a tumor suppressor.
|
24968760 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGF2R was overexpressed significantly more frequently in HR negative tumors (p = 0.001) and had an inverse correlation with all other biomarkers.
|
24637962 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that M6P/IGF2R truncation mutants may contribute to the cancer phenotype by decreasing the availability of full-length M6P/IGF2Rs to perform tumor-suppressive functions such as binding/internalization of receptor ligands such as insulin-like growth factor II.
|
22681933 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
rs629849" genes_norm="3482">Gly1619Arg polymorphism of IGF2R domain 11 (rs629849) was assessed in blood samples of 113 individuals with histology-confirmed OSCC, and IGF2R genotypes were correlated with the stage of tumor (localized; TMN stages I-II versus advanced; TMN stages III-IV).
|
21347719 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Several single-nucleotide polymorphisms of IGF1R, IGF2R, and IRS1 gene were significantly associated with tumor response to therapy and disease stage.
|
20416304 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of IGF2R and LATS1 candidate tumor suppressor genes at 6q was reduced in more than 50% of GSD Ia HCA that were examined (n = 7).
|
19762333 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGF2R has been proposed to be a tumor suppressor gene given its antagonist role on cellular growth and evidence of loss of heterozygosity in several cancers, including breast cancer.
|
19435860 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) encodes a protein that plays a critical role in tumor suppression, in part by modulating bioavailability of a potent mitogen, insulin-like growth factor-2 (IGF2).
|
19626700 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For IGF2R and CTCF, 71% (25 out of 35) and 50% (17/34), respectively, of the samples were heterozygous, and LOH was detected in 12% (3 out of 25) and 6% (1 out of 17), respectively, of the tumors.
|
18604514 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R.
|
18322954 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In humans, adult tissues lack IGF2R imprinted expression, but it is found in fetal tissues and Wilms' tumors where it is polymorphic and only seen in a small proportion of tested samples.
|
18789384 |
2008 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To determine potential association(s) between A2/B2 presence and development and/or progression of disease, we examined in 103 NSCLC patients, free of IGF2R allelic imbalance aberrations, the 3' UTR allelic status in relation to tumor kinetic parameters (proliferation index-PI and apoptotic index-AI) and clinicopathological data.
|
18037232 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2r), a member of the IGF axis of growth factors, is a negative regulator of cell growth and a putative tumor suppressor gene.
|
17295243 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development.
|
16779663 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The M6P/IGF2R gene was polymorphic in 83.7% (36/43) of patients, and 41.7% (15/36) of these informative patients had LOH in the tumor tissue.
|
16304558 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest requirement for the cell surface targets IGF2R, L1CAM and SLC31A1 in tumor cell growth in vitro, and suggests that IGF2R is required for xenograft tumor growth in a mouse model.
|
15361835 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Urokinase-type plasminogen activator receptor (uPAR) binding by the mannose 6-phosphate/insulin-like growth factor II receptor (Man-6-P/IGF2R) is considered important to Man-6-P/IGF2R tumor suppressor function via regulation of cell surface proteolytic activity.
|
12665524 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Concomitant chemotherapy resulted in a better outcome when compared to radiotherapy alone only in those patients whose tumors had M6P/IGF2R loss of heterozygosity.
|
12589712 |
2003 |